All IndicationsRare & Genetic Diseases
🧬
Paroxysmal Nocturnal Hemoglobinuria (PNH) in complement inhibitor treatment-naive patients
1
Companies
1
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| NVCT Nuvectis Pharma, Inc. | NXP100 | Approved | — | — | — |
Development Stage Distribution
Approved
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.